Spiro-rifamycin derivatives targeting RNA polymerase
    22.
    发明申请
    Spiro-rifamycin derivatives targeting RNA polymerase 有权
    螺 - 利福霉素衍生物靶向RNA聚合酶

    公开(公告)号:US20050277633A1

    公开(公告)日:2005-12-15

    申请号:US11147520

    申请日:2005-06-08

    IPC分类号: A61K31/498 A61K31/542

    CPC分类号: C07D491/22

    摘要: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

    摘要翻译: 本发明的化合物涉及具有抗微生物活性的利福霉素衍生物,包括抗耐药微生物的活性。 更具体地,本发明的化合物涉及一系列已经证明有效的抗微生物活性的新型螺利福霉素衍生物。

    Anti-infective agents useful against multidrug-resistant strains of bacteria
    23.
    发明授权
    Anti-infective agents useful against multidrug-resistant strains of bacteria 有权
    对多药耐药菌株有效的抗感染剂

    公开(公告)号:US06946446B2

    公开(公告)日:2005-09-20

    申请号:US09791408

    申请日:2001-02-23

    CPC分类号: C07H17/08 A61K31/335

    摘要: The invention relates to novel methods for using macrolide anti-infective agents. The macrolide anti-infective agents demonstrate antibacterial activity against multi-drug resistant strains of bacteria and, in particular, methicillin-resistant Staphylococcus aureus (MRSA). Methods for inhibiting the activity of multi-drug resistant bacterial organisms and methods for treating a bacterial infection caused by such organisms are described herein.

    摘要翻译: 本发明涉及使用大环内酯类抗感染剂的新方法。 大环内酯类抗感染剂表现出抗多药耐药菌株,特别是耐甲氧西林金黄色葡萄球菌(MRSA)的抗菌活性。 本文描述了抑制多药耐药性细菌生物体的活性的方法和用于治疗由此类生物引起的细菌感染的方法。

    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
    27.
    发明授权
    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes 有权
    对抗耐药微生物有效的利福霉素C-11肟环衍生物

    公开(公告)号:US07265107B2

    公开(公告)日:2007-09-04

    申请号:US11076173

    申请日:2005-03-09

    申请人: Jing Li Zhenkun Ma

    发明人: Jing Li Zhenkun Ma

    CPC分类号: C07D498/18

    摘要: The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.

    摘要翻译: 本发明涉及一系列具有抗菌活性的利福霉素衍生物,包括抗药性微生物的活性,具体地说,具有C-11位上肟基的3,4-环 - 利福霉素衍生物。

    C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
    28.
    发明授权
    C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes 有权
    C-25氨基甲酸酯利福霉素衍生物,具有抗药性的微生物活性

    公开(公告)号:US07250413B2

    公开(公告)日:2007-07-31

    申请号:US11114384

    申请日:2005-04-26

    摘要: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

    摘要翻译: 本发明的化合物涉及具有抗微生物活性的利福霉素衍生物,包括抗耐药微生物的活性。 更具体地,本发明的化合物涉及具有另一官能团的利福霉素的C-25氨基甲酸酯衍生物或通过氨基甲酸酯键共价连接到该位置的药效团。 所得化合物通过双功能机制发挥其抗微生物活性,因此表现出降低的抗性频率。

    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
    30.
    发明申请
    Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes 有权
    对抗耐药微生物有效的利福霉素C-11肟环衍生物

    公开(公告)号:US20050203085A1

    公开(公告)日:2005-09-15

    申请号:US11076173

    申请日:2005-03-09

    申请人: Jing Li Zhenkun Ma

    发明人: Jing Li Zhenkun Ma

    IPC分类号: A61K31/5383 A61K31/5415

    CPC分类号: C07D498/18

    摘要: The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.

    摘要翻译: 本发明涉及一系列具有抗菌活性的利福霉素衍生物,包括抗药性微生物的活性,具体地说,具有C-11位上肟基的3,4-环 - 利福霉素衍生物。